Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Airway Sensitivity of HFA-152a vs HFA-134a Propellants in Mild Asthma
NCT06702462Phase 1Completed
- Sponsor
- GSK
- Start
- Mar 2025
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HFA-152a in asthma (2 arms), sponsored by GSK. Primary endpoint: Percentage Change From Baseline in Forced Expiratory Volume in 1 Second at 15 months. Started Mar 2025; status: completed.
02
Drugs
HFA-152a
03
Conditions
asthma
Beyond the preview
Go deeper on NCT06702462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06702462.